Bengaluru: Anthem Biosciences Limited (BSE: 544449 | NSE: ANTHEM | INE0CZ201020), an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (“CRDMO”), announced unaudited Consolidated Financial Results for the quarter ended June 30, 2026 as
approved by its Board of Directors on Tuesday.
Q1FY27 Financial Highlights:
Q1FY27 Key Financial Highlights:
- Consolidated Revenue from Operations was ₹4,182 Mn for the quarter
o CRDMO business delivered ₹3,408 Mn revenues
o Specialty Ingredients delivered ₹774 Mn revenues - EBITDA was ₹1,755 Mn, with EBITDA margins at 39.6%
o EBITDA for Q1FY27 includes Other Income of ₹249 Mn (Q1FY26: ₹228 Mn) - Other Operating Income on account of forex gain (net) and RoDTEP incentives is ₹13 Mn (Q1FY26: ₹37 Mn)
- Financial and other Non-Operating Income is ₹236 Mn (Q1FY26: ₹191 Mn)
- PBT was ₹1,446 Mn
- PAT (Profit After Tax) was ₹1,199 Mn, with PAT margins at 27.1%
Ajay Bhardwaj, Chairman, MD and CEO, Anthem Biosciences Limited, said: “Our Q1FY27 quarterly results reflect timing shifts in deliveries to key customers. The underlying demand remains strong, and with a higher concentration of scheduled deliveries in the latter half of the year, we are positioned to capture that momentum. We remain firmly committed to sustaining revenue growth aligned with our long-term historical performance. On the margin front, we delivered year-on-year improvement across both EBITDA and PAT margins.
Our disciplined focus on cost efficiencies, yield optimization, and employee productivity continues to reinforce our industry-leading margin profile, positioning us to sustain this performance through the year.”
